Al's Comment:

 This is a new STAT3 inhibitor. STAT3 has been known as a good target for brain tumors but until now we did not have a good drug to target it. This was just the first in human doses of the drug so it is way too early to tell if it will work, but it may become an important tool in the ultimate cocktail.


Posted on: 09/13/2018

Moleculin’s Brain Cancer Drug Candidate Begins Patient Dosing at Clinical Trial Being Conducted at MD Anderson

 


Click HERE to return to brain tumor news headlines.


Our privacy / cookie policy has changed.
Click HERE to read it!